Medtronic (Medtronic) Cash, Cash Equivalents, Marketable Securities

: $8,321 Mil (As of Jan. 2024)

View and export this data going back to 1980. Start your Free Trial

Medtronic's quarterly cash, cash equivalents, marketable securities declined from Jul. 2023 ($7,876.00 Mil) to Oct. 2023 ($7,734.00 Mil) but then increased from Oct. 2023 ($7,734.00 Mil) to Jan. 2024 ($8,321.00 Mil).

Medtronic's annual cash, cash equivalents, marketable securities declined from Apr. 2021 ($10,817.00 Mil) to Apr. 2022 ($10,573.00 Mil) and declined from Apr. 2022 ($10,573.00 Mil) to Apr. 2023 ($7,959.00 Mil).

Medtronic Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Medtronic's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medtronic Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

9,848.00

10,948.00

10,817.00

10,573.00

7,959.00

Medtronic Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															11,137.00	7,959.00	7,876.00	7,734.00	8,321.00

Medtronic Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Medtronic (NYSE:MDT) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Medtronic Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Medtronic's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Medtronic (Medtronic) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medtronic PLC (NYSE:MDT) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

MDTN:Mexico 1MDT:Italy 2M6:Germany 2M6:Germany 2M6:Germany 2M6:Germany MDTC34:Brazil MDT:Austria MDT:Argentina

Address

Lower Hatch Street, 20 On Hatch, Dublin, IRL, 2

Website

https://www.medtronic.com

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.

Executives

Brett A. Wall	officer: EVP & Group Pres Restora Thera	710 MEDTRONIC PARKWAY, LC300, MINNEAPOLIS MN 55432
Gregory L Smith	officer: EVP Global Ops & Supply Chain	710 MEDTRONIC PARKWAY, LC300, MINNEAPOLIS MN 55432
Michael Marinaro	officer: EVP & President, Surgical OU	710 MEDTRONIC PARKWAY NE, LC300, MINNEAPOLIS MN 55432
Hoedt Rob Ten	officer: EVP & President EMEAC	710 MEDTRONIC PKWY, MSLC300, MINNEAPOLIS MN 55432
Gregory P Lewis	director	C/O HONEYWELL INTERNATIONAL INC., 300 SOUTH TRYON STREET, CHARLOTTE NC 28202
Sean Salmon	officer: EVP & Group President Diabetes	MEDTRONIC PLC, 710 MEDTRONIC PARKWAY, LC300, MINNEAPOLIS MN 55432
Lidia Fonseca	director	358 SOUTH MAIN STREET, BURLINGTON NC 27215
Karen L Parkhill	officer: EVP & Chief Financial Officer	1717 MAIN STREET, MC 6402, DALLAS TX 75201
Ivan K Fong	officer: EVP GENERAL COUNSEL & SECR	3M CENTER, ST. PAUL MN 55144-1000
Robert John White	officer: EVP & President MITG	MEDTRONIC PLC, 710 MEDTRONIC PKWY MS LC300, MINNEAPOLIS MN 55432
Richard H Anderson	director	MEDTRONIC, INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Bradley E Lerman	officer: SVP General Counsel & Corp Sec	MEDTRONIC, INC., 710 MEDTRONIC PKWY MSLC300, MINNEAPOLIS MN 55432
Geoffrey Martha	officer: Sr VP, Strategy & Bus Dev	710 MEDTRONIC PKWAY, MS LC300, MINNEAPOLIS MN 55432
Jennifer M Kirk	officer: Chief Accounting Officer	5 GREENWAY PLAZA, SUITE 110, HOUSTON TX 77046
John R Liddicoat	officer: EVP & President of Americas	MEDTRONIC PLC, 710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432